Evgen Pharma PLC Nominated Adviser Status (0079K)
10 Dicembre 2018 - 4:00PM
UK Regulatory
TIDMEVG
RNS Number : 0079K
Evgen Pharma PLC
10 December 2018
10 December 2018
Evgen Pharma plc
("Evgen" or the "Company")
Nominated Adviser Status
The directors are aware of the proposed merger of its nominated
adviser, Northland Capital Partners Limited ("Northland") with SP
Angel Corporate Finance LLP ("SP Angel"). The directors have also
been informed that Northland has voluntarily agreed to relinquish
its nominated adviser status and will be removed from the register
of nominated advisers with effect from 7.00 a.m. on 1 February
2019.
The Company is currently in discussions with alternative
nominated advisers and is confident that a suitable replacement
will be appointed in January 2019.
In accordance with AIM Rule 1, in the unlikely event that the
Company fails to appoint a new nominated adviser by 1 February
2019, the Exchange will suspend trading in the Company's AIM
Securities. If the Company has failed to appoint a replacement
nominated adviser by 4 March 2019 the admission of its AIM
Securities will be cancelled.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
Buchanan
Mark Court, Sophie Wills, Tilly Abraham +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney (Corporate
Finance)
Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office at the Liverpool Science Park, Liverpool. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCTMBITMBABBJP
(END) Dow Jones Newswires
December 10, 2018 10:00 ET (15:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024